SCHEMBL1603737

SCHEMBL1603737

CC(C)N(C(C)C)P(O)OC(C)(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1763992 0.75
SCHEMBL14684459 0.73 MAPK1 (0.30)
SCHEMBL2479770 0.72
SCHEMBL5930 0.72
SCHEMBL6513766 0.71
SCHEMBL8586814 0.70
SCHEMBL19160447 0.70
SCHEMBL4445861 0.69
SCHEMBL2453974 0.67
SCHEMBL1061098 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023140369-A1 PHOSPHORIC ACID DERIVATIVES Prism BioLab Co., Ltd. (JP) 2023-07-27 WO disclosed
WO-2023102523-A1 THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION GILEAD SCIENCES, INC. (US) 2023-06-08 WO disclosed
WO-2022191338-A1 LEVODOPA-PRODRUGS AND CARBIDOPA-PRODRUGS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2022-09-15 WO disclosed
EP-3953361-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OF COVID-19 Pfizer Inc. (US) 2022-02-16 EP disclosed
US-9809609-B2 Water-soluble benzoazepine compound and its pharmaceutical composition OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2017-11-07 US disclosed
US-9303052-B2 Water-soluble benzoazepine compound and its pharmaceutical composition I. OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2016-04-05 US disclosed
EP-1968990-B1 WATER-SOLUBLE BENZOAZEPINE COMPOUND AND ITS PHARMACEUTICAL COMPOSITION OTSUKA PHARMA CO LTD (JP) 2015-02-11 EP disclosed
EP-2674436-A1 Water-soluble benzoazepine compound and its pharmaceutical composition OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-12-18 EP disclosed
US-20130331358-A1 Water-Soluble Benzoazepine Compound and Its Pharmaceutical Composition OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-12-12 US disclosed
US-20120277189-A1 WATER-SOLUBLE BENZOAZEPINE COMPOUND AND ITS PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. 2012-11-01 US disclosed
US-20080318901-A1 Novel Lysophosphatidic Acid Receptor Selective Antagonists UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2008-12-25 US disclosed
WO-2008058156-A9 GUGGULPHOSPHOLIPID METHODS AND COMPOSITIONS JINA PHARMACEUTICALS INC (US) 2008-12-04 WO disclosed
EP-1968990-A1 WATER-SOLUBLE BENZOAZEPINE COMPOUND AND ITS PHARMACEUTICAL COMPOSITION Otsuka Pharmaceutical Co., Ltd. (JP) 2008-09-17 EP disclosed
WO-2008058156-A2 GUGGULPHOSPHOLIPID METHODS AND COMPOSITIONS JINA PHARMACEUTICALS INC. (US) 2008-05-15 WO disclosed
EP-1546110-A4 COMPOUNDS ACTIVE IN SPHINGOSINE 1-PHOSPHATE SIGNALING UNIV VIRGINIA (US) 2008-03-26 EP disclosed
US-7241790-B2 Compounds active in spinigosine 1-phosphate signaling UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2007-07-10 US disclosed
WO-2007074915-A1 WATER-SOLUBLE BENZOAZEPINE COMPOUND AND ITS PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-07-05 WO disclosed
EP-1546110-A2 COMPOUNDS ACTIVE IN SPHINGOSINE 1-PHOSPHATE SIGNALING University of Virginia Patent Foundation (US) 2005-06-29 EP disclosed
WO-2005041899-A2 ORALLY AVAILABLE SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONISTS AND ANTAGONISTS UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2005-05-12 WO disclosed
WO-2004010949-A2 COMPOUNDS ACTIVE IN SPINIGOSINE 1-PHOSPHATE SIGNALING UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2004-02-05 WO disclosed